Difference between revisions of "MDM2"

From Libre Pathology
Jump to navigation Jump to search
(create)
 
Line 4: Line 4:
*[[Liposarcoma]].
*[[Liposarcoma]].


Note:
Aberant:  
*May be positive in [[fat necrosis]].
*May be positive in [[fat necrosis]].
*[[Angiomyolipoma]].<ref name=pmid27369456>{{Cite journal  | last1 = Asch-Kendrick | first1 = RJ. | last2 = Shetty | first2 = S. | last3 = Goldblum | first3 = JR. | last4 = Sharma | first4 = R. | last5 = Epstein | first5 = JI. | last6 = Argani | first6 = P. | last7 = Cimino-Mathews | first7 = A. | title = A subset of fat-predominant angiomyolipomas label for MDM2: a potential diagnostic pitfall. | journal = Hum Pathol | volume = 57 | issue =  | pages = 7-12 | month = Nov | year = 2016 | doi = 10.1016/j.humpath.2016.06.014 | PMID = 27369456 }}</ref>


==References==
==References==

Revision as of 17:25, 5 March 2017

MDM2 is an immunostain used in soft tissue pathology.

Positive

Aberant:

References

  1. Asch-Kendrick, RJ.; Shetty, S.; Goldblum, JR.; Sharma, R.; Epstein, JI.; Argani, P.; Cimino-Mathews, A. (Nov 2016). "A subset of fat-predominant angiomyolipomas label for MDM2: a potential diagnostic pitfall.". Hum Pathol 57: 7-12. doi:10.1016/j.humpath.2016.06.014. PMID 27369456.